Inotek Pharmaceuticals Corp  

(Public, NASDAQ:ITEK)   Watch this stock  
Find more results for ITEK
0.00 (0.00%)
Pre-market: 1.70 0.00 (0.00%)
Jan 20, 9:07AM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.65 - 10.90
Open     -
Vol / Avg. 100.00/1.57M
Mkt cap 45.12M
P/E     -
Div/yield     -
EPS -1.43
Shares 26.93M
Beta     -
Inst. own 104%
Mar 21, 2017
Q4 2016 Inotek Pharmaceuticals Corp Earnings Release (Estimated) Add to calendar
Jan 3, 2017
Inotek Pharmaceuticals Conference Call to Discuss Top-line MATrX-1 Results - Webcast
Nov 29, 2016
Inotek Pharmaceuticals Corp at Piper Jaffray Healthcare Conference - Webcast
Nov 16, 2016
Inotek Pharmaceuticals Corp at Stifel Healthcare Conference
Nov 14, 2016
Inotek Pharmaceuticals Corp at Mizuho Global Investor Conference
Nov 9, 2016
Q3 2016 Inotek Pharmaceuticals Corp Earnings Release
Nov 2, 2016
Inotek Pharmaceuticals Corp at Boston Biotech NY/NJ CEO Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -37.20% -114.41%
Return on average equity -49.46% -237.93%
Employees 17 -
CDP Score - -


91 Hartwell Ave Ste 2
LEXINGTON, MA 02421-3130
United States - Map
+1-781-6762100 (Phone)
+1-781-6762155 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Officers and directors

J. Martin Carroll Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
David P. Southwell President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Dale Ritter Vice President—Finance, Principal Financial and Accounting Officer, Treasurer, Secretary
Age: 65
Bio & Compensation  - Reuters
Rudolf Baumgartner M.D. Executive Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Paul G. Howes Director
Age: 59
Bio & Compensation  - Reuters
Timothy Joseph Barberich Independent Director
Age: 68
Bio & Compensation  - Reuters
Carsten Boess Independent Director
Age: 49
Bio & Compensation  - Reuters
Ittai Harel Independent Director
Age: 48
Bio & Compensation  - Reuters
Patrick Machado J.D. Independent Director
Age: 52
Bio & Compensation  - Reuters